Skip to main content
. Author manuscript; available in PMC: 2015 May 21.
Published in final edited form as: Cancer Cell Microenviron. 2015 Mar 16;2(1):e677. doi: 10.14800/ccm.677

Figure 2. Antiangiogenic TKIs reduce tumor vascularity, leading to increased oxygenation.

Figure 2

(A) C57/BL6 mice were treated as indicated beginning 14 days post-implantation of MC38-CEA cells. Mice receiving vaccine received a priming vaccination of MVA-CEA/TRICOM on day 14 and a booster vaccination of rF-CEA/TRICOM on day 21. Tumors were harvested 28 days post-tumor implantation. Images show representative tumor areas at 20x magnification obtained using an Aperio ScanScope. (B) Seven days post-implantation of MC38-CEA cells, indicated mice began receiving sunitinib. MVA-CEA/TRICOM was given on day 14. Tumors were harvested 21 days post-tumor implantation. Images show representative tumor areas at 40x magnification obtained using an Aperio ScanScope. In both cases, tumors were harvested and double-stained for the vascular markers CD31 and CD105 using DAB for visualization. Representative images adapted from [12] and [15] are shown. (C) C57/BL6 mice were treated as in (B). IHC analysis of hypoxia was performed using Hypoxyprobe-DAB. Images show representative tumors at 2x magnification obtained using an Aperio ScanScope. Data adapted from [15].